Shares of Perspective Therapeutics (NYSE:CATX) traded higher on Wednesday after Truist launched its coverage with a Buy recommendation and a $21 per share target, arguing that its pipeline focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback